Needham Maintains Buy on NeoGenomics, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a Buy rating on NeoGenomics (NASDAQ:NEO) and raises the price target from $21 to $24.
February 21, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Mike Matson maintains a Buy rating on NeoGenomics and raises the price target from $21 to $24.
The increase in the price target by a reputable analyst suggests a positive outlook on the company's future performance, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100